Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$16.20

0.77% today

NYSE, Feb 28, 04:47 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$16.32

+4.11 33.66% 5Y

NYSE, Closing price Thu, Feb 27 2025

-0.46 2.74%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$18.70b
Enterprise Value	$33.91b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	16.62
EV/Sales (TTM) EV/Sales	2.05
P/S ratio (TTM) P/S ratio	1.13
P/B ratio (TTM) P/B ratio	3.44
Revenue growth (TTM) Revenue growth	4.34%
Revenue (TTM) Revenue	$16.53b
EBIT (operating result TTM) EBIT	$3.35b
Free Cash Flow (TTM) Free Cash Flow	$2.04b
Cash position	$3.30b
EPS (TTM) EPS	$-1.45
P/E forward	11.49
P/S forward	1.09
EV/Sales forward	1.98
Short interest	1.98%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

9x Buy

75%

3x Hold

25%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy

75%

Hold

25%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	16,531 16,531	4% 4% 100%
- Direct Costs	8,480 8,480	3% 3% 51%
Gross Profit	8,051 8,051	5% 5% 49%
- Selling and Administrative Expenses	2,642 2,642	13% 13% 16%
- Research and Development Expense	999 999	5% 5% 6%
EBITDA	4,410 4,410	1% 1% 27%
- Depreciation and Amortization	1,059 1,059	8% 8% 6%
EBIT (Operating Income) EBIT	3,351 3,351	5% 5% 20%
Net Profit	-1,638 -1,638	211% 211% -10%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

one day ago

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states

Neutral

GlobeNewsWire

●

3 days ago

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL) announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted ...

Neutral

Seeking Alpha

●

4 days ago

Teva Pharmaceutical Industries Limited (TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference (Transcript)

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference February 24, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Eric Hughes - Head of R&D & Chief Medical Officer Vipul Jairath - Professor at Western University Conference Call Participants Umer Raffat - Evercore ISI Ash Verma - UBS Dav...

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Employees	36,167
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now